Tirzepatide Research Information
GLP-1 / GIP Receptor Agonist
Dual Hormone Receptor Agonist for Metabolic Research
⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
📑 Contents
🔬 What is Tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist that mimics the action of two naturally occurring hormones involved in metabolic regulation. It is a 39-amino acid peptide with a C20 fatty acid side chain that extends its half-life.
Unlike semaglutide which targets only GLP-1, tirzepatide targets both GLP-1 and GIP receptors, making it a dual-agonist approach for appetite regulation and glycemic control.
⚡ How Tirzepatide Works
Tirzepatide works by mimicking two naturally occurring hormones that regulate appetite, blood sugar, and energy balance:
GLP-1
Reduces appetite, slows digestion, enhances insulin secretion
GIP
Improves insulin sensitivity, supports metabolic health
Combined, these mechanisms promote reduced food intake, improved insulin response, and better blood sugar control.
📋 Research Applications
Tirzepatide has been extensively studied across multiple clinical trials, with research focusing on:
Weight Management
Evaluated for weight reduction in individuals with obesity or overweight
Type 2 Diabetes
Assessed for glycemic control (HbA1c reduction) in type 2 diabetes
Cardiovascular Health
Demonstrated cardiovascular benefits in patients with established cardiovascular disease
Metabolic Research
Investigating effects on non-alcoholic fatty liver disease (NAFLD) and other metabolic conditions
📊 Clinical Studies
SURMOUNT Trials (Weight Management)
The SURMOUNT clinical trial program evaluated tirzepatide for weight management:
| Trial | Duration | Weight Loss (15mg) | Weight Loss (Placebo) |
|---|---|---|---|
| SURMOUNT-1 | 72 weeks | −20.9% | −3.1% |
| SURMOUNT-2 | 72 weeks | −15.7% | −3.3% |
| SURMOUNT-3 | 72 weeks | −18.4% | −3.5% |
Key finding: At the 15 mg dose, participants lost an average of 20.9% of their body weight after 72 weeks.
SURPASS Trials (Type 2 Diabetes)
The SURPASS trial program evaluated tirzepatide for glycemic control in type 2 diabetes:
- Significant HbA1c reductions of 1.8-2.4% across multiple trials
- Weight loss of 6-12 kg in patients with type 2 diabetes
- Cardiovascular benefits demonstrated in the SURPASS-CVOT trial
💉 Interactive Dosing Guide
Select your pen size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per pen:
🖊️ Step 1: Select Your Pen Size
💊 Step 2: Select Your Dose
Pen Size
30mg Pen
Selected Dose
2.5 mg
Doses per Pen
12 doses
Pen Clicks
25 clicks
Volume
0.25 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Once weekly - Once weekly - Loading Phase (Weeks 1-4)
⚠️ Do not change your dose unless advised by a qualified professional.
📋 Protocol Level Summary
| Protocol Level | Target Dose | Frequency | Pen Clicks | Volume (mL) | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 2.5 mg | Once weekly | 25 clicks | 0.25 mL | New users, first 4 weeks |
| Level 2 (Standard) | 5 mg | Once weekly | 50 clicks | 0.50 mL | After 4 weeks, maintenance |
| Level 3 (Intermediate) | 7.5 mg | Once weekly | 75 clicks | 0.75 mL | If hunger cravings return |
| Level 4 (Advanced) | 10 mg | Once weekly | 100 clicks | 1.00 mL | If more response needed |
| Level 5 (Maximum) | 15 mg | Once weekly | 150 clicks | 1.50 mL | Experienced users only |
⚠️ Do not change your dose unless advised by a qualified professional.
💉 Vial Users (Insulin Syringe)
Select your vial size to see the units on an insulin syringe (all vials use 3mL bac water):
Vial Size
30mg vial with 3mL bac water
| Dose | Units on Syringe | Volume (mL) | Protocol Level | |
|---|---|---|---|---|
| 2.5 mg | Once weekly | 25 units | 0.25 mL | Level 1 |
| 5 mg | Once weekly | 50 units | 0.50 mL | Level 2 |
| 7.5 mg | Once weekly | 75 units | 0.75 mL | Level 3 |
| 10 mg | Once weekly | 100 units | 1.00 mL | Level 4 |
| 15 mg | Once weekly | 150 units | 1.50 mL | Level 5 |
⚠️ Always use a new sterile needle and syringe for each injection.
⚠️ Safety & Precautions
Do not use if you:
- Are allergic to tirzepatide or any ingredients
- Have type 1 diabetes
- Are pregnant or breastfeeding
- Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
Common side effects:
- Nausea (usually improves over time)
- Diarrhoea (usually improves over time)
- Vomiting
- Constipation
- Abdominal pain
- Decreased appetite, weight loss
- Injection site reactions
⚠️ Warning: If you experience severe and ongoing stomach pain, difficulty breathing, or signs of a severe allergic reaction, seek immediate medical help.
📚 References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1)
- Garvey WT, et al. "Tirzepatide in Patients with Type 2 Diabetes and Obesity." The Lancet. 2023;401:109-121. (SURPASS-2)
- ClinicalTrials.gov. "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight." NCT04184622.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026